The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | COVID-19 and the future of lung cancer treatment in the UK
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks about the impacts of the COVID-19 pandemic on the treatment of lung cancer, highlighting the importance of recovering diagnostic and treatment services, and the future role of screening and neoadjuvant and adjuvant immunotherapy. Dr Newsom-Davis also discusses the use of KRAS inhibitors, such as sotorasib, and antibody-drug conjugates. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, has received support to attend educational conferences from AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Otsuka, Roche and Takeda; has participated in an advisory role for Amgen, Bayer, AstraZeneca, BMS, Boehringer Ingelheim, Eli-Lilly, Janssen, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi and Takeda; and has participated in speaker’s bureaus for AstraZeneca, MSD, Roche and Takeda; and has participated in an independent data monitoring committee for Blueprint.
